Han Yi Rang, Lee Ping I
Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto , Toronto, Ontario M5S 3M2, Canada.
Mol Pharm. 2017 Jan 3;14(1):206-220. doi: 10.1021/acs.molpharmaceut.6b00788. Epub 2016 Nov 28.
Solubility limited compounds require enabling formulations such as amorphous solid dispersions (ASDs) to increase the apparent solubility by dissolving to a concentration higher than the equilibrium solubility of the drug. This may lead to subsequent precipitation and thus the loss of the solubility advantage. Although higher supersaturation is known to result in faster precipitation, the overall effect of this faster precipitation on the bioavailability is not well understood. The objective of this study is to gain a better understanding of the impact of extent of supersaturation (i.e., dose) on the resulting kinetic solubility profiles of supersaturating dosage forms. Experimental concentration-time curves of two model compounds with different recrystallization tendencies, indomethacin (IND) and naproxen (NAP), were explored under varying sink indices (SIs) by infusing varying volumes of dissolved drug (e.g., in ethanol) into the dissolution medium. The experimental results were simulated with a mechanistic model considering classical nucleation theory and interface controlled growth on the nucleus surface. In the absence of dissolved polymer to inhibit precipitation, experimental and predicted results show that there exists a critical supersaturation below which no precipitation is observed, and due to this supersaturation maintenance, there exists an optimal dose which maximizes the area under the curve (AUC) of the kinetic solubility concentration-time profile. In the presence of dissolved polymer from ASD dissolution, similar trends were observed except the critical supersaturation was increased due to crystallization inhibition by the dissolved polymer. The importance of measuring the experimental "kinetic solubility" is emphasized. However, we show that the true solubility advantage of amorphous solids depends not on the "kinetic solubility" of amorphous dosage forms, typically arising from the balance between the rate of supersaturation generation and the precipitation kinetics, but rather on the critical supersaturation below which precipitation is not observed for a sufficiently long period.
溶解度受限的化合物需要借助诸如无定形固体分散体(ASD)等赋形剂来提高表观溶解度,使其溶解至高于药物平衡溶解度的浓度。这可能会导致随后的沉淀,进而丧失溶解度优势。尽管已知更高的过饱和度会导致更快的沉淀,但这种更快沉淀对生物利用度的总体影响尚不清楚。本研究的目的是更好地理解过饱和度程度(即剂量)对过饱和剂型所得动力学溶解度曲线的影响。通过将不同体积的溶解药物(如在乙醇中)注入溶出介质,在不同的漏槽条件(SI)下探究了两种具有不同重结晶倾向的模型化合物吲哚美辛(IND)和萘普生(NAP)的实验浓度 - 时间曲线。实验结果用一个考虑经典成核理论和核表面界面控制生长的机理模型进行模拟。在没有溶解聚合物抑制沉淀的情况下,实验和预测结果表明存在一个临界过饱和度,低于该值未观察到沉淀,并且由于这种过饱和度维持存在一个最佳剂量,可使动力学溶解度浓度 - 时间曲线的曲线下面积(AUC)最大化。在存在来自ASD溶解产生的溶解聚合物的情况下,观察到类似趋势,只是由于溶解聚合物的结晶抑制作用,临界过饱和度增加。强调了测量实验“动力学溶解度”的重要性。然而我们表明,无定形固体真正的溶解度优势并不取决于无定形剂型的“动力学溶解度”(通常源于过饱和度产生速率和沉淀动力学之间的平衡),而是取决于临界过饱和度,低于该值在足够长的时间内未观察到沉淀。